ArkBio Receives China IND Approval for Influenza Prophylaxis Candidate AK0406

Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) has received Investigational New Drug (IND) approval from China's regulatory authorities for its drug candidate AK0406. The compound is designed as a long-acting antiviral drug-Fc conjugate (AFC) for the prevention of influenza.

This approval allows ArkBio to proceed with clinical trials in China for AK0406. The company aims to develop a new option for influenza prophylaxis, potentially offering longer-lasting protection compared to existing treatments.

ArkBio has not yet released specific timelines for the initiation or expected outcomes of the clinical studies. The IND approval marks a significant milestone in the drug's development pathway.